Cannabinoid 1 receptor in fatty liver

Hepatology Research

Volumn 43, Issue 2, 2013, Pages 131-138

  Regnell, Simon Eringsmark ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Cannabinoid receptor CB1; Fatty liver; Hepatic steatosis; Non alcoholic fatty liver disease; Sterol regulatory element binding protein 1c

Indexed keywords

ACETYL COENZYME A ACETYLTRANSFERASE; ACTIVATING TRANSCRIPTION FACTOR 6; ADENYLATE CYCLASE; CANNABINOID; CANNABINOID 1 RECEPTOR; CARNITINE PALMITOYLTRANSFERASE I; CHOLESTEROL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FATTY ACID; GLUCAGON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LIVER X RECEPTOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; RIMONABANT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

CHOLESTEROL SYNTHESIS; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW;

EID: 84873954007     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01085.x     Document Type: Review

References (78)

1. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172 (7): 899-905.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346 (16): 1221-1231.
3. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006; 290 (5): G852-858.
4. Hamaguchi M, Kojima T, Takeda N etal. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143 (10): 722-728.
5. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2 (3): 262-265.
6. Regnell SE, Lernmark A. Hepatic steatosis in type 1 diabetes. Rev Diabet Stud 2011; 8 (4): 454-467.
7. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004; 24 (4): 399-413.
8. Kim HJ, Kim HJ, Lee KE etal. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164 (19): 2169-2175.
9. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006; 82 (967): 315-322.
10. Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Bátkai S. Endocannabinoids and the control of energy homeostasis. J Biol Chem 2008; 283 (48): 33021-33025.
11. Hézode C, Zafrani ES, Roudot-Thoraval F etal. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008; 134 (2): 432-439.
12. Liu J, Zhou L, Xiong K etal. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012; 142 (5): 1218-1228.
13. Gary-Bobo M, Elachouri G, Gallas JF etal. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007; 46 (1): 122-129.
14. Kunos G, Tam J. The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 2011; 163 (7): 1423-1431.
15. 1 cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 2009; 30 (1): 1-7.
16. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109 (9): 1125-1131.
17. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89 (3): 331-340.
18. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997; 99 (5): 838-845.
19. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009; 48 (1): 1-26.
20. Jourdan T, Djaouti L, Demizieux L, Gresti J, Vergès B, Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010; 59 (4): 926-934.
21. Sone H, Shimano H, Sakakura Y etal. Acetyl-coenzyme A synthetase is a lipogenic enzyme controlled by SREBP-1 and energy status. Am J Physiol Endocrinol Metab 2002; 282 (1): E222-230.
22. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114 (2): 147-152.
23. Zhao W, Fong O, Muise ES etal. Genome-wide expression profiling revealed peripheral effects of cannabinoid receptor 1 inverse agonists in improving insulin sensitivity and metabolic parameters. Mol Pharmacol 2010; 78 (3): 350-359.
24. Sundqvist A, Bengoechea-Alonso MT, Ye X etal. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab 2005; 1 (6): 379-391.
25. Repa JJ, Liang G, Ou J, Bashmakov Y etal. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14 (22): 2819-2830.
26. Wu HM, Yang YM, Kim SG. Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gαi/o inhibition. Mol Pharmacol 2011; 80 (5): 859-869.
27. Yamamoto T, Shimano H, Inoue N etal. Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver. J Biol Chem 2007; 282 (16): 11687-11695.
28. Dash PK, Karl KA, Colicos MA, Prywes R, Kandel ER. cAMP response element-binding protein is activated by Ca2+/calmodulin- as well as cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 1991; 88 (11): 5061-5065.
29. Childers SR, Deadwyler SA. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem Pharmacol 1996; 52 (6): 819-827.
30. Azzout-Marniche D, Bécard D, Guichard C, Foretz M, Ferré P, Foufelle F. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J 2000; 350 (Pt 2): 389-393.
31. Im SS, Kang SY, Kim SY etal. Glucose-stimulated upregulation of GLUT2 gene is mediated by sterol response element-binding protein-1c in the hepatocytes. Diabetes 2005; 54 (6): 1684-1691.
32. Foretz M, Pacot C, Dugail I etal. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol 1999; 19 (5): 3760-3768.
33. Berglund ED, Lustig DG, Baheza RA etal. Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver. Diabetes 2011; 60 (11): 2720-2729.
34. Minokoshi Y, Alquier T, Furukawa N etal. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004; 428 (6982): 569-574.
35. Huang X, Wullschleger S, Shpiro N etal. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008; 412 (2): 211-221.
36. Collins SP, Reoma JL, Gamm DM, Uhler MD. LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem J 2000; 345 (Pt 3): 673-680.
37. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G etal. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118: 3160-3169.
38. Jeong WI, Osei-Hyiaman D, Park O etal. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008; 7 (3): 227-235.
39. You M, Crabb DW. Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins. Alcohol 2004; 34 (1): 39-43.
40. García-Villafranca J, Guillén A, Castro J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver. Biochimie 2008; 90 (3): 460-466.
41. Esfandiari F, You M, Villanueva JA, Wong DH, French SW, Halsted CH. S-adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate-deficient diet. Alcohol Clin Exp Res 2007; 31 (7): 1231-1239.
42. Zhou G, Myers R, Li Y etal. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108 (8): 1167-1174.
43. Li Y, Xu S, Mihaylova MM, Zheng B etal. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13 (4): 376-388.
44. Wakil SJ, Abu-Elheiga LA. Fatty acid metabolism: target for metabolic syndrome. J Lipid Res 2009; 50: S138-143.
45. Hwahng SH, Ki SH, Bae EJ, Kim HE, Kim SG. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 2009; 49 (6): 1913-1925.
46. Lage R, Diéguez C, Vidal-Puig A, López M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 2008; 14 (12): 539-549.
47. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 1997; 244 (1): 1-14.
48. Ruderman NB, Saha AK, Vavvas D, Witters LA. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 1999; 276 (1 Pt 1): E1-E18.
49. Abu-Elheiga L, Brinkley WR, Zhong L, Chirala SS, Woldegiorgis G, Wakil SJ. The subcellular localization of acetyl-CoA carboxylase 2. Proc Natl Acad Sci U S A 2000; 97 (4): 1444-1449.
50. Flamment M, Gueguen N, Wetterwald C, Simard G, Malthièry Y, Ducluzeau PH. Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 2009; 297 (5): E1162-1170.
51. Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 2003; 27 (Suppl 3): S17-21.
52. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005; 54 (8): 2460-2470.
53. Hsu MH, Savas U, Griffin KJ, Johnson EF. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J Biol Chem 2001; 276 (30): 27950-27958.
54. Hegardt FG. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. Biochem J 1999; 338 (Pt 3): 569-582.
55. Meng R, Pei Z, Zhang A eal. AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway. Arch Biochem Biophys 2011; 511 (1-2): 1-7.
56. Ozaita A, Puighermanal E, Maldonado R. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 2007; 102 (4): 1105-1114.
57. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129 (7): 1261-1274.
58. Laplante M, Sabatini DM. mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proc Natl Acad Sci U S A 2010; 107 (8): 3281-3282.
59. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A. Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 2009; 12 (9): 1152-1158.
60. Pearson G, Robinson F, Beers Gibson T etal. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22 (2): 153-183.
61. Teixeira-Clerc F, Julien B, Grenard P etal. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006; 12 (6): 671-676.
62. Rozenfeld R, Devi LA. Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J 2008; 22 (7): 2311-2322.
63. Roth G, Kotzka J, Kremer L etal. MAP kinases Erk1/2 phosphorylate sterol regulatory element-binding protein (SREBP)-1a at serine 117 in vitro. J Biol Chem 2000; 275 (43): 33302-33307.
64. Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004; 86 (11): 839-848.
65. Smith TM, Gilliland K, Clawson GA, Thiboutot D. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 2008; 128 (5): 1286-1293.
66. Yki-Järvinen H. Fat in the liver and insulin resistance. Ann Med 2005; 37 (5): 347-356.
67. Amarapurka DN, Amarapurkar AD, Patel ND etal. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann Hepatol 2006; 5 (1): 30-33.
68. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368 (9548): 1660-1672.
69. Kim SP, Woolcott OO, Hsu IR etal. CB1 antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs. Am J Physiol Endocrinol Metab 2012; 302 (10): E1261-1268.
70. 6K activities in the liver of obese Zucker rats. J Endocrinol 2009; 203 (3): 337-347.
71. Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006; 147 (2): 943-951.
72. Werstuck GH, Lentz SR, Dayal S etal. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001; 107 (10): 1263-1273.
73. Puri P, Mirshahi F, Cheung O etal. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008; 134 (2): 568-576.
74. Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739-789.
75. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2000; 2 (6): 326-332.
76. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999; 397 (6716): 271-274.
77. Bloch-Damti A, Potashnik R, Gual P etal. Differential effects of IRS1 phosphorylated on Ser307 or Ser632 in the induction of insulin resistance by oxidative stress. Diabetologia 2006; 49 (10): 2463-2473.
78. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005; 18 (1): 13-24.